Corrado Tamburino1, MD, PhD; Nicolo Piazza2, MD, PhD; Andreas Baumbach3, MD; Stephan Windecker4, MD, PhD; Francesco Maisano5, MD; Bernard D. Prendergast6, MD
1. Division of Cardiology, CAST Policlinico Hospital, University of Catania, Catania, Italy; 2. McGill University Health Centre, Montreal, QC, Canada; 3. Barts Heart Centre, Queen Mary University of London, London, United Kingdom; 4. Department of Cardiology, Bern University Hospital “Inselspital”, Bern, Switzerland; 5. Klinik fur Herz- und Gefässchirurgie, UniversitatsSpital Zurich, Zurich, Switzerland; 6. Department of Cardiology, St Thomas’ Hospital, London, United Kingdom
The last decade has seen tremendous growth in transcatheter therapies for valvular heart disease (VHD), with 2019 being a special year embracing ground-breaking achievements. In particular, clinical evidence has now reached a level sufficient to support expanded indications for different transcatheter valve interventions, prompting the need to refine optimal patient management and device use further.
In the field of transcatheter aortic valve implantation (TAVI), two recent randomised clinical trials comparing TAVI with surgical aortic valve replacement (SAVR) extend the large body of evidence concerning these two procedures to patients at low surgical risk. In the PARTNER 3 trial1, transfemoral TAVI ...
